Premium
Potential pathophysiological mechanisms in osteonecrosis of the jaw
Author(s) -
Landesberg Regina,
Woo Victoria,
Cremers Serge,
Cozin Matthew,
Marolt Darja,
VunjakNovakovic Gordana,
Kousteni Stavroula,
Raghavan Srikala
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2010.05835.x
Subject(s) - osteonecrosis of the jaw , medicine , malignancy , disease , pathophysiology , osteoporosis , bisphosphonate , bone density conservation agents , intensive care medicine , bioinformatics , pathology , bone density , biology
Bisphosphonates are used in the treatment of hypercalcemia of malignancy, skeletal complications associated with metastastic bone disease, Paget's disease, and osteoporosis. Osteonecrosis of the jaw (ONJ) is a recently described clinical condition that has been associated with the use of nitrogen‐containing bisphosphonates. Reports describing this entity first appeared in the literature in 2003. While there have been significant numbers of case reports and a limited number of retrospective and prospective studies examining risk factors associated with ONJ, the pathophysiology of this condition remains elusive. In this review, we explore proposed mechanisms underlying ONJ development and identify potential areas for future investigation.